AUG 6·SEC EDGARLow
Luo Peter purchased $85K of ADAG
Luo Peter (Chief Executive Officer) purchased 23,245 shares of Adagene Inc. (ADAG) at an average of $3.65 ($3.65–$3.65) across 2 trades over 2026-08-04 to 2026-08-05.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ADAG
Adagene Inc.
Price · $ADAGvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ADAG in the last 7 days.
Insider · 30dAll trades →
- Buys
- $85K 2 txs
- Sells
- — 0 txs
Luo Peter2× · $85K
10b5-1 plan0%
Top stories · $ADAGMore →
APR 14·GlobeNewswire
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
Adagene Inc. has appointed Peter Lebowitz, MD, Ph.D. to its Scientific and Strategic Advisory Board. Dr. Lebowitz, formerly Global Head of Oncology R&D at Johnson & Johnson, brings extensive experience in drug development and is recognized for his contributions to advancing novel therapies from discovery to commercialization. His expertise will guide the continued clinical development of Adagene's lead program, ADG126, a masked anti-CTLA-4 SAFEbody, particularly in strategies for registration-enabling studies and exploring future combination approaches.
JAN 23·GlobeNewswire
Adagene Provides Business Update and 2026 Objectives
Adagene Inc. announced unaudited cash and cash equivalents of $74.5 million as of December 31, 2025, providing a sufficient financial runway into late 2027. The company highlighted key accomplishments from 2025, including progress in its muzastotug clinical trials and strategic collaborations with Sanofi, Third Arc Bio, Exelixis, and ConjugateBio. Adagene also outlined its 2026 objectives, focusing on further clinical data updates for muzastotug in various cancer indications and securing additional partnerships.
ADAG sentiment & insider activity
Recent ADAG coverage spans financial news and insider activity.
In the last 30 days, ADAG insiders filed 2 SEC Form 4 transactions — 2 purchases ($85K) and no sales. The most active reporter was Luo Peter, Chief Executive Officer, with 2 filings.
What's driving ADAG
The Form 4 discloses an insider buy, but it is not a fundamental catalyst like guidance, trial results, or a deal.
The appointment of a prominent oncology R&D expert to Adagene's advisory board signals strategic focus on advancing clinical programs, particularly ADG126. This may positively influence investor sentiment and potentially lead to increased stock valuation.
Adagene's positive financial position and progress in clinical trials suggest potential upside for the company's stock. Strategic collaborations and upcoming clinical data releases could act as catalysts.
The FDA's fast track designation for ADAG's lead drug, muzastotug (ADG126), signals strong potential for accelerated development and approval, likely leading to positive investor sentiment and a short-term stock price increase.
The FDA's fast track designation for ADG106, an anti-CD137 antibody, indicates accelerated development and potential near-term clinical milestones, which could positively influence ADAG stock performance.
alphai scores every news story that mentions ADAG with an AI model for sentiment and relevance, and aggregates insider trades from Adagene Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ADAG
Score
Luo Peter purchased $85K of ADAG
Luo Peter (Chief Executive Officer) purchased 23,245 shares of Adagene Inc. (ADAG) at an average of $3.65 ($3.65–$3.65) across 2 trades over 2026-08-04 to 2026-08-05.
2 min read
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
Adagene Inc. has appointed Peter Lebowitz, MD, Ph.D. to its Scientific and Strategic Advisory Board. Dr. Lebowitz, formerly Global Head of Oncology R&D at Johnson & Johnson, brings extensive experience in drug development and is recognized for his contributions to advancing novel therapies from discovery to commercialization. His expertise will guide the continued clinical development of Adagene's lead program, ADG126, a masked anti-CTLA-4 SAFEbody, particularly in strategies for registration-enabling studies and exploring future combination approaches.
3 min read
Adagene Provides Business Update and 2026 Objectives
Adagene Inc. announced unaudited cash and cash equivalents of $74.5 million as of December 31, 2025, providing a sufficient financial runway into late 2027. The company highlighted key accomplishments from 2025, including progress in its muzastotug clinical trials and strategic collaborations with Sanofi, Third Arc Bio, Exelixis, and ConjugateBio. Adagene also outlined its 2026 objectives, focusing on further clinical data updates for muzastotug in various cancer indications and securing additional partnerships.
3 min read
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug
Adagene Inc. (ADAG) announced that the FDA granted Fast Track designation to its lead clinical-stage immuno-oncology candidate, muzastotug (ADG126), in combination with Merck’s Keytruda for treating adult patients with microsatellite-stable metastatic colorectal cancer. This designation aims to facilitate drug development and expedite review for serious diseases with unmet medical needs. ADAG shares surged 13.8% following the announcement, reflecting positive investor sentiment.
3 min readAdagene shares jump after FDA awards fast track status to cancer treatment
Adagene Inc. shares rose significantly after the FDA granted fast track designation to its differentiated anti-CD137 agonist antibody, ADG106, for advanced solid tumors and non-Hodgkin lymphoma. This designation aims to accelerate the development and review of treatments for serious conditions with unmet medical needs. ADG106 is currently in Phase I clinical trials in both the U.S. and China.
4 min readAdagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with ...
3 min read
All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
3 min read
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
3 min read
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
4 min read
Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - Adagene (NASDAQ:ADAG)
SAN DIEGO and SUZHOU, China, Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Adagene Inc. ( "Adagene or the Company" ) ADAG, a company transforming the discovery and development of novel antibody-based therapies, today announced that ADG126 will be highlighted in two oral presentations at this year's CSCO ...
3 min read